» Articles » PMID: 21071688

Influence of Apolipoprotein A-I Domain Structure on Macrophage Reverse Cholesterol Transport in Mice

Overview
Date 2010 Nov 13
PMID 21071688
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The goal of this study was to determine the influence of apolipoprotein A-I (apoA-I) tertiary structure domain properties on the antiatherogenic properties of the protein. Two chimeric hybrids with the N-terminal domains swapped (human-mouse apoA-I and mouse-human apoA-I) were expressed in apoA-I-null mice with adeno-associated virus (AAV) and used to study macrophage reverse cholesterol transport (RCT) in vivo.

Methods And Results: The different apoA-I variants were expressed in apoA-I-null mice that were injected with [H(3)]cholesterol-labeled J774 mouse macrophages to measure RCT. Significantly more cholesterol was removed from the macrophages and deposited in the feces via the RCT pathway in mice expressing mouse-H apoA-I compared with all other groups. Analysis of the individual components of the RCT pathway demonstrated that mouse-H apoA-I promoted ATP-binding cassette transporter A1-mediated cholesterol efflux more efficiently than all other variants, as well as increasing the rate of cholesterol uptake into liver cells.

Conclusions: The structural domain properties of apoA-I affect the ability of the protein to mediate macrophage RCT. Replacement of the N-terminal helix bundle domain in the human apoA-I with the mouse apoA-I counterpart causes a gain of function with respect to macrophage RCT, suggesting that engineering some destabilization into the N-terminal helix bundle domain or increasing the hydrophobicity of the C-terminal domain of human apoA-I would enhance the antiatherogenic properties of the protein.

Citing Articles

Connecting Cholesterol Efflux Factors to Lung Cancer Biology and Therapeutics.

Maslyanko M, Harris R, Mu D Int J Mol Sci. 2021; 22(13).

PMID: 34281263 PMC: 8268178. DOI: 10.3390/ijms22137209.


The Susceptibility to Diet-Induced Atherosclerosis Is Exacerbated with Aging in C57B1/6 Mice.

Simo O, Berrougui H, Fulop T, Khalil A Biomedicines. 2021; 9(5).

PMID: 33946646 PMC: 8146644. DOI: 10.3390/biomedicines9050487.


Swapping the N- and C-terminal domains of human apolipoprotein E3 and AI reveals insights into their structure/activity relationship.

Lek M, Cruz S, Ibe N, Beck W, Bielicki J, Weers P PLoS One. 2017; 12(6):e0178346.

PMID: 28644829 PMC: 5482431. DOI: 10.1371/journal.pone.0178346.


Transfer of C-terminal residues of human apolipoprotein A-I to insect apolipophorin III creates a two-domain chimeric protein with enhanced lipid binding activity.

Horn J, Ellena R, Tran J, Beck W, Narayanaswami V, Weers P Biochim Biophys Acta Biomembr. 2017; 1859(8):1317-1325.

PMID: 28434970 PMC: 5518692. DOI: 10.1016/j.bbamem.2017.04.017.


The effect of Chinese herbs and its effective components on coronary heart disease through PPARs-PGC1α pathway.

Wang Q, Li C, Zhang Q, Wang Y, Shi T, Lu L BMC Complement Altern Med. 2016; 16(1):514.

PMID: 27955667 PMC: 5153825. DOI: 10.1186/s12906-016-1496-z.


References
1.
Yancey P, Bortnick A, Kellner-Weibel G, de la Llera-Moya M, Phillips M, Rothblat G . Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol. 2003; 23(5):712-9. DOI: 10.1161/01.ATV.0000057572.97137.DD. View

2.
Alexander E, Tanaka M, Kono M, Saito H, Rader D, Phillips M . Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I. J Lipid Res. 2009; 50(7):1409-19. PMC: 2694339. DOI: 10.1194/jlr.M800578-JLR200. View

3.
Vedhachalam C, Liu L, Nickel M, Dhanasekaran P, Anantharamaiah G, Lund-Katz S . Influence of ApoA-I structure on the ABCA1-mediated efflux of cellular lipids. J Biol Chem. 2004; 279(48):49931-9. DOI: 10.1074/jbc.M406924200. View

4.
Dullaart R, Perton F, Sluiter W, de Vries R, Van Tol A . Plasma lecithin: cholesterol acyltransferase activity is elevated in metabolic syndrome and is an independent marker of increased carotid artery intima media thickness. J Clin Endocrinol Metab. 2008; 93(12):4860-6. DOI: 10.1210/jc.2008-1213. View

5.
Rader D . Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest. 2006; 116(12):3090-100. PMC: 1679714. DOI: 10.1172/JCI30163. View